Back to Search

International Partner Search

Innovation & Technology Offer

Novel pharmaceutical composition for anaplastic thyroid carcinoma

Country of Origin: South Korea
Reference Number: TOKR20170321001
Publication Date: 21 March 2017


A Korean company specialised in biomedical science has developed a new treatment for anaplastic thyroid carcinoma. The new pharmaceutical composition will enable to cure undifferentiated thyroid cancer. The company is looking for partners to make license agreement with or progress joint research and development.


A Korean SME has been interested in developing new medicines through integrating oriental and western medicine. They have 5 R&D institutions and 19 pipelines including natural substances and synthetic medicines. They also have interest in intractable and rare diseases. There has been no medicine for anaplastic thyroid carcinoma which is hard to trace and treat because the tumor has a problem absorbing iodine, unlike other differentiated thyroid cancer cells. The company has developed an effective medicine for undifferentiated thyroid cancer.

Anaplastic thyroid cancer (ATC) is one of the most aggressive and lethal cancers known to affect humans. The prevalence rate of anaplastic thyroid carcinoma is relatively low compared to other types of thyroid cancer. However, once it has occurred, it has been really difficult to treat the disease. The medicine for the cancer has not been developed, so the prognosis is not good and it is connected to high death rate. Also, it has been almost impossible to cure small size of metastasized cancer, because it is invisible and untraceable.

The developed medicine from the company has solved those problems. It is a synthesized single compound that controls estrogen related receptor γ (ERR γ) and increases the absorption rate of radioactive isotopes into the target cancer cells. The medicine makes it possible to track the iodinated cancer and reduce the mass size of the anaplastic thyroid cancer.

The company is interested in companies to cooperate on further research and tests together. They have finished developing the medicine and additional tests are going on. They are looking for partners to progress joint research and have license agreement.

Advantages and Innovations

-It is almost nontoxic as a result of toxicity test.
-It is predicted to be highly secure to be used as anticancer medicine and adjuvant.
-It can increase the absorptivity of radioactive isotopes.(Iodine Uptake)
-It can be also helpful to treat the cancer which is metastasised by anaplastic thyroid carcinoma.

Stage Of Development

Available for demonstration

Stage Of Development Comment

-Non-GLP study will be started in 2017(US)
-In vitro ∙ in vivo tests completed and effectiveness proved
-2 weeks repeated dose toxicity testing completed
-PK test completed
-Scale up (GMP level) will be executed in 2017(Korea)

Requested partner

Type of partner sought 
-SME and larger company

Specific area of activity of partner
-western medicine, oriental medicine, undifferentiated thyroid cancer

Tasks to be performed by the partner sought
-Research cooperation and License agreement

Contact Profile Owner